课题基金 / 基金详情

The role of microtubule composition in the efficacy of antimicrotubule agents in paediatric malignancy

The role of microtubule composition in the efficacy of antimicrotubule agents in paediatric malignancy
微管组成在抗微管药物治疗儿科恶性肿瘤疗效中的作用
批准号:
nhmrc : 113837
负责人:
Prof Maria Kavallaris
金额:
$11.56万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2000
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2000-01-01 至 2002-12-31

项目摘要

项目成果

Prof Maria Kavallaris的其他基金

相似基金

相关文献

中文摘要
翻译
为了加强对儿童和成人癌症的管理,需要更好地了解肿瘤侵袭性和耐药性的过程。微管是细胞的重要结构成分,对于细胞正常分裂至关重要。这使得微管成为抗癌药物的极好靶点,抗癌药物可以破坏微管并杀死癌细胞。这项提案将确定肿瘤细胞的微管组成是否会预测某些癌症的侵袭性,以及这是否会影响哪些肿瘤对长春花生物碱产生反应。长春花生物碱是一类重要的天然产物药物,其破坏微管并且在成人和儿童癌症的治疗中特别有效。不幸的是,由于耐药性的发展,一些癌细胞对这种治疗没有反应。这项提案解决了儿童对长春花生物碱的耐药性?它将决定为什么某些癌细胞治疗失败。此外,这项研究将确定微管的某些成分的作用,这些成分似乎与白血病和神经母细胞瘤细胞的耐药性有关,其作用尚不清楚。化学药物,如长春花生物碱,在癌症治疗中很重要,了解它们与细胞靶点的相互作用将改善新药的设计和治疗效果。
英文摘要
To enhance the management of both childhood and adult cancers improved understanding of the processes responsible for tumour aggressiveness and drug resistance are required. Microtubules are important structural components of cells which are crucial for normal cell division. This makes microtubules excellent targets for anticancer drugs which can disrupt microtubules and kill cancer cells. This proposal will identify whether the microtubule composition of a tumour cell will predict for the aggressiveness of certain cancers, and whether this influences which tumours will respond to the vinca alkaloids. The vinca alkaloids are an important class of natural product drugs which disrupt microtubules and are particularly effective in the treatment of adult and childhood cancers. Unfortunately, some cancer cells fail to respond to this treatment due to the development of drug resistance. This proposal addresses vinca alkaloid resistance in children?s cancer and will determine why certain cancer cells fail treatment. Furthermore, this study will identify the role of certain components of microtubules that appear to be related to drug resistance in leukaemia and neuroblastoma cells and whose role is unknown. Chemotherapeutic drugs, such as the vinca alkaloids, are important in the treatment of cancer and knowledge about their interaction with their cellular target will improve the design of new drugs and treatment outcome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precision nanomedicine-based cancer therapeutics
  • 批准号:
    nhmrc : GNT1119152
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $76.38万
  • 财政年份:
    2017
  • 负责人:
    Prof Maria Kavallaris
  • 依托单位:
Precision nanomedicine-based cancer therapeutics
  • 批准号:
    nhmrc : 1119152
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $52.22万
  • 财政年份:
    2017
  • 负责人:
    Prof Maria Kavallaris
  • 依托单位:
Regulation & targeting of the cancer cytoskeleton
  • 批准号:
    nhmrc : 1058299
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $41.72万
  • 财政年份:
    2014
  • 负责人:
    Prof Maria Kavallaris
  • 依托单位:
Structural domains of beta-tubulin and their role in microtubule dynamics and transport
  • 批准号:
    DP140103290
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $23.97万
  • 财政年份:
    2014
  • 负责人:
    Prof Maria Kavallaris
  • 依托单位:
国内基金
海外基金
纤毛相关激酶受RNA编辑调控的机理研究
  • 批准号:
    32100538
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李冬冬
  • 依托单位:
用于对微管动态结构实时定量分析的荧光探针
  • 批准号:
    32070708
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    谢松波
  • 依托单位:
Kinesin-8调控微管动态及减数分裂I期同源染色体分离的分子机制
  • 批准号:
    32070707
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    符传孩
  • 依托单位:
微管结合蛋白WDR62调节有丝分裂纺锤体极微管负端动态性的功能及机制
  • 批准号:
    32070705
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    姜恺
  • 依托单位: